pp-225 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Major Depressive Disorder (MDD)
Clinical stage: Phase 2
Modality: Small molecule serotonin modulator
Mechanism & Target: SERT modulator
Route & form: Oral
Differentiation: Novel mechanism for treatment-resistant depression
Manufacturer #39433
Clinical-stage biopharmaceutical company specializing in central nervous system disorders. Develops novel small molecules targeting psychiatric, neurological, and rare CNS conditions. Pursues multiple Phase 2 and Phase 3 programs through global development initiatives.
None